Minseok Suh1,2, Hyung-Jun Im2,3, Hyun Gee Ryoo1,2, Keon Wook Kang1, Jae Min Jeong1, Sneha Prakash4, Sanjana Ballal4, Madhav P Yadav4, Chandrasekhar Bal4, Chang Wook Jeong5, Cheol Kwak5, Gi Jeong Cheon6,7,8. 1. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea. 2. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea. 3. Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea. 4. Department of Nuclear Medicine, AIIMS, New Delhi, India. 5. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. 6. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea; larrycheon@gmail.com. 7. Cancer Research Institute, Seoul National University, Seoul Korea; and. 8. Institute of Radiation Medicine, College of Medicine, Seoul National University, Seoul, Korea.
Abstract
68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)-targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.
68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)-targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.
Authors: Sung-Hyun Moon; Mee Kyung Hong; Young Ju Kim; Yun-Sang Lee; Dong Soo Lee; June-Key Chung; Jae Min Jeong Journal: Bioorg Med Chem Date: 2018-04-05 Impact factor: 3.641
Authors: Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2017-06 Impact factor: 9.236
Authors: Christian Schmidkonz; Michael Cordes; Daniela Schmidt; Tobias Bäuerle; Theresa Ida Goetz; Michael Beck; Olaf Prante; Alexander Cavallaro; Michael Uder; Bernd Wullich; Peter Goebell; Torsten Kuwert; Philipp Ritt Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-03 Impact factor: 9.236
Authors: Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger Journal: J Nucl Med Date: 2015-03-19 Impact factor: 10.057
Authors: Manthena V S Varma; Bo Feng; R Scott Obach; Matthew D Troutman; Jonathan Chupka; Howard R Miller; Ayman El-Kattan Journal: J Med Chem Date: 2009-08-13 Impact factor: 7.446
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236